Press Releases for CLRT

Press Releases
Health Discovery Corporation Announces Additional Issued Patents and Notices of Allowance to Its Intellectual Property Portfolio
Safeguard Scientifics Announces Sale of 2.4 Million Additional Clarient Shares Pursuant to Overallotment Option
Safeguard Scientifics Announces Second Quarter 2009 Financial Results
Clarient to Present at Canaccord Adams 29th Annual Global Growth Conference on Wednesday, August 12th
Clarient Reports Second Quarter Revenue Up 40 Percent ; New Molecular Tests and Increased Case Volume Continue to Drive Revenue Growth; First Net Income Reported; Revenue Guidance Increased
Clarient Reports Second Quarter Revenue Up 40 Percent
Clarient to Release 2009 Second Quarter Financial Results On Tuesday, August 4th
Emerging Growth Equities, Ltd. Initiates Coverage of Clarient, Inc. With a Buy Rating and $4.50 Price Target
Health Discovery Corporation Announces Publication of Peer Reviewed Scientific Paper Demonstrating the Clinical Validity of the Four-Gene Prostate Cancer Test Licensed to Abbott, Quest Diagnostics and Clarient
Clarient Set to Join Russell 3000 Index
Clarient Launches New Gene Mutation Test to Help Select Therapy for Non-Small Cell Lung Cancer
Clarient to Present at Noble Financial's 5th Annual Equity Conference on Tuesday, June 9th
Clarient Completes Second Tranche of Private Placement of Convertible Preferred Stock With Oak Investment Partners
Safeguard Scientifics Announces First Quarter 2009 Financial Results
Clarient Reports 41% Revenue Increase for First Quarter 2009
Clarient Launches New Breast Cancer Test
Clarient to Release First Quarter 2009 Financial Results On Wednesday, May 6th
Clarient Granted Exclusive License to Commercialize Breast Cancer Biomarker by Indiana University Research and Technology Corporation
Clarient Entered Into Private Placement of Up To $50 Million in Convertible Preferred Stock With Oak Investment Partners
Clarient to Present at the Cowen and Company 29th Annual Health Care Conference on Tuesday, March 17th
Clarient Reports Strong Revenue Increase for Fourth Quarter and Full-Year 2008
Clarient Reschedules Fourth Quarter and Year-End 2008 Financial Results Release To Wednesday, March 11th; Conference Call and Webcast Rescheduled For 5:00 PM EDT That Day
Clarient Renews and Expands Mezzanine Credit Facility With Safeguard
Clarient to Release Fourth Quarter and Year-End 2008 Financial Results On Wednesday, March 4th
Clarient to Present at the Roth Capital Partners 21st Annual OC Growth Stock Conference on Wednesday, February 18th
Clarient Issues Performance Update to Shareholders; Expects Continued Robust Profitable Growth in 2009
Clarient Extends Maturities of $20 Million in Existing Credit Facilities
Clarient Launches Gene Expression Test for Prostate Cancer
Clarient’s Insight Dx Breast Cancer Profile Validated by New Data
Clarient Introduces Second Gene Mutation Test for Colorectal Cancer
Clarient to Present at the Rodman & Renshaw Healthcare Conference on November 12
Clarient Reports Third Quarter Revenue up 59%; Achieves First Operating Profit
Clarient Names Dr. Todd S. Barry as Medical Director
Clarient to Release Third Quarter 2008 Financial Results on Wednesday, October 29
[video] Ronald Andrews, CEO of Clarient, Inc. Discusses Agreement With University of Pennsylvania School of Medicine on WallSt.net's 3-Minute Press Show
Clarient Enters into Training and Consulting Agreement with University of Pennsylvania School of Medicine
Clarient and Definiens Collaborate to Develop Image Analysis Technology for Cancer Diagnostics
Clarient to Present at the Baird Small Cap Health Care Conference on September 10
Clarient Reports Second Quarter Revenue Up 71%
Clarient and Health Discovery Corporation Announce Results from Prostate Profile Clinical Validation Studies
Clarient Announces $8 Million Accounts Receivable Financing Agreement With Gemino Healthcare Finance
Clarient to Release Second Quarter 2008 Financial Results on Wednesday, August 6
Clarient Launches New Colorectal Cancer Test
CombiMatrix Announces the Acceptance of Its Multi-Institute Study On the Use of HemeScan for CLL by Journal, Expert Opinions in Molecular Diagnostics
Clarient Names Raymond J. Land Senior Vice President and Chief Financial Officer
Jim Agnello to Resign as Clarient Chief Financial Officer - May 27 2008 1:34AM
Clarient Partners With Joint Venture Hospital Laboratories to Offer Pathologists Wide Array of Cancer Assays - Jun 1 2008 4:26PM
Clarient Reports First Quarter 2008
Clarient Continues to Augment Organization to Support Profitable Growth
Clarient to Release First Quarter 2008 Financial Results On Wednesday, April 30